Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Cardiomyopathy IV: Restrictive Cardiomyopathy01:29

Cardiomyopathy IV: Restrictive Cardiomyopathy

113
Restrictive cardiomyopathy (RCM) is a rare heart muscle disease characterized by impaired ventricular filling due to stiffened ventricular walls, leading to significant diastolic dysfunction.EtiologyRestrictive cardiomyopathy can arise from both inherited and acquired diseases, many of which are systemic. It is categorized into four main types: infiltrative, storage, non-infiltrative, and endomyocardial diseases.Infiltrative diseases, such as amyloidosis, lead to RCM by depositing amyloid...
113
Regulation of Metabolism01:19

Regulation of Metabolism

10.4K
Cellular needs and conditions vary from cell to cell and change within individual cells over time. For example, the required enzymes and energetic demands of stomach cells are different from those of fat storage cells, skin cells, blood cells, and nerve cells. Furthermore, a digestive cell works much harder to process and break down nutrients during the time that closely follows a meal compared with many hours after a meal. As these cellular demands and conditions vary, so do the amounts and...
10.4K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Targeting the cGAS-STING pathway for therapeutic gain in autoimmune inflammatory cutaneous diseases with a focus on systemic lupus erythematosus and systemic sclerosis.

The British journal of dermatology·2025
Same author

The Role of the Pulmonary Microenvironment in Driving Transition From Systemic Sclerosis to Systemic Sclerosis-Associated Interstitial Lung Disease.

The Journal of rheumatology·2025
Same author

A Long Stretch: IL-11 Drives Skin Regeneration.

The Journal of investigative dermatology·2025
Same author

Extracellular BAG3 is elevated in early diffuse systemic sclerosis.

Military Medical Research·2025
Same author

The metabolic drivers of IFN-γ release: glycolysis and acetyl CoA ride in the front seat.

Journal of immunology (Baltimore, Md. : 1950)·2025
Same author

Aberrant fumarate metabolism links interferon release in diffuse systemic sclerosis.

Journal of dermatological science·2025

Related Experiment Video

Updated: Oct 17, 2025

Imaging Features of Systemic Sclerosis-Associated Interstitial Lung Disease
04:44

Imaging Features of Systemic Sclerosis-Associated Interstitial Lung Disease

Published on: June 16, 2020

20.4K

Metabolic perturbations in systemic sclerosis.

Steven O'Reilly1

  • 1Department of Biosciences, Durham University, Durham, UK.

Current Opinion in Rheumatology
|October 12, 2021
PubMed
Summary

Metabolic aberrations, including altered glycolysis and glutaminolysis, are implicated in systemic sclerosis (SSc) fibrosis. Targeting these metabolic pathways may offer novel therapeutic strategies for SSc.

Area of Science:

  • Immunology and Metabolism
  • Rheumatology
  • Fibrotic Diseases

Background:

  • Systemic sclerosis (SSc) is an autoimmune disease characterized by vascular issues, inflammation, and progressive fibrosis, particularly in the skin and lungs.
  • Current antifibrotic treatments for SSc remain ineffective, necessitating exploration of novel therapeutic avenues.
  • Recent research highlights the critical role of cellular metabolism in immune function and disease pathogenesis.

Purpose of the Study:

  • To review current evidence on the role of metabolism in systemic sclerosis (SSc).
  • To identify specific metabolic aberrations contributing to SSc pathogenesis.
  • To assess the therapeutic potential of targeting identified metabolic pathways in SSc.

Main Methods:

  • Comprehensive literature review of recent studies investigating metabolic alterations in SSc.

More Related Videos

Vasodilation of Isolated Vessels and the Isolation of the Extracellular Matrix of Tight-skin Mice
08:09

Vasodilation of Isolated Vessels and the Isolation of the Extracellular Matrix of Tight-skin Mice

Published on: March 24, 2017

8.2K
Phosphorus-31 Magnetic Resonance Spectroscopy: A Tool for Measuring In Vivo Mitochondrial Oxidative Phosphorylation Capacity in Human Skeletal Muscle
09:40

Phosphorus-31 Magnetic Resonance Spectroscopy: A Tool for Measuring In Vivo Mitochondrial Oxidative Phosphorylation Capacity in Human Skeletal Muscle

Published on: January 19, 2017

11.9K

Related Experiment Videos

Last Updated: Oct 17, 2025

Imaging Features of Systemic Sclerosis-Associated Interstitial Lung Disease
04:44

Imaging Features of Systemic Sclerosis-Associated Interstitial Lung Disease

Published on: June 16, 2020

20.4K
Vasodilation of Isolated Vessels and the Isolation of the Extracellular Matrix of Tight-skin Mice
08:09

Vasodilation of Isolated Vessels and the Isolation of the Extracellular Matrix of Tight-skin Mice

Published on: March 24, 2017

8.2K
Phosphorus-31 Magnetic Resonance Spectroscopy: A Tool for Measuring In Vivo Mitochondrial Oxidative Phosphorylation Capacity in Human Skeletal Muscle
09:40

Phosphorus-31 Magnetic Resonance Spectroscopy: A Tool for Measuring In Vivo Mitochondrial Oxidative Phosphorylation Capacity in Human Skeletal Muscle

Published on: January 19, 2017

11.9K
  • Analysis of data linking specific metabolic pathways (e.g., glycolysis, glutaminolysis) to SSc fibroblasts and fibrosis.
  • Evaluation of evidence for reduced nicotinamide adenine dinucleotide (NAD+) levels in SSc.

    • Main Results:

    • Alterations in glycolysis and glutaminolysis are identified in SSc fibroblasts, contributing to fibrosis.
    • Reduced nicotinamide adenine dinucleotide (NAD+) levels have been observed in SSc.
    • Specific metabolic dysregulations are increasingly recognized as key players in SSc pathology.

    Conclusions:

    • Metabolic aberrations are significantly associated with the pathogenesis of systemic sclerosis.
    • These identified metabolic pathways represent promising targets for developing novel antifibrotic therapies for SSc.
    • Further research into SSc metabolism could unlock new treatment strategies.